Basel-Country

Basel-Landschaft is the suburban and industrial counterpart to Basel-Stadt, forming the larger half of the Basel metropolitan area. With a population of approximately 295,000, a GDP of CHF 20 billion, and an area of 518 square kilometers, the canton provides the residential, logistics, and manufacturing infrastructure that supports the Basel region's globally significant pharma and life sciences cluster.

The pharma supply chain is the canton's defining economic feature. Companies like Bachem (peptide CDMO in Bubendorf), Syngenta (agrochemical research in Stein and Muenchenstein), and hundreds of smaller contract manufacturers, laboratory suppliers, and packaging firms form a deep industrial ecosystem. The Switzerland Innovation Park Basel Area in Allschwil is rapidly becoming a major life sciences campus, attracting biotech start-ups and established firms seeking state-of-the-art facilities adjacent to the Basel pharma cluster.

Industrial manufacturing and automation constitute another pillar, anchored by Endress+Hauser's global headquarters in Reinach. The canton hosts a significant concentration of precision measurement, process automation, and industrial engineering firms that serve customers across Switzerland and internationally. This sector creates high-value jobs and generates consistent M&A interest from PE platforms and strategic buyers.

Logistics and warehousing are naturally strong given the canton's position between EuroAirport, the Rhine port, and the A2 motorway corridor to the Gotthard. The sector is consolidating, with both organic growth and M&A driving the emergence of larger, integrated logistics providers.

From a tax perspective, Basel-Landschaft's 18.5% effective corporate rate is notably higher than Basel-Stadt's 13.0%, creating competitive tension within the metropolitan area. The canton compensates with significantly lower real estate costs, ample commercial space, and a quieter quality of life that appeals to families. The succession landscape involves approximately 3,000 at-risk companies, concentrated in the pharma supply chain, construction, and traditional manufacturing sectors.